MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

TG Therapeutics Inc

Gesloten

SectorGezondheidszorg

39.18 -1.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

38.04

Max

40

Belangrijke statistieken

By Trading Economics

Inkomsten

19M

23M

Verkoop

24M

108M

K/W

Sectorgemiddelde

262.867

63.778

EPS

0.15

Winstmarge

21.566

Werknemers

338

EBITDA

17M

33M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.48% upside

Dividenden

By Dow Jones

Volgende Winsten

30 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

6.3B

Vorige openingsprijs

40.66

Vorige sluitingsprijs

39.18

Nieuwssentiment

By Acuity

61%

39%

336 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

TG Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 aug 2024, 20:01 UTC

Winsten

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Peer Vergelijking

Prijswijziging

TG Therapeutics Inc Prognose

Koersdoel

By TipRanks

7.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 42.8 USD  7.48%

Hoogste 55 USD

Laagste 10 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor TG Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

5

Buy

0

Hold

1

Sell

Technische score

By Trading Central

39.43 / 42.8Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

336 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.